Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5881 AL 5895

Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology

Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P.

CNS Neurol Disord Drug Targets. 2011 Feb;10(1):57-67. doi: 10.2174/187152711794488665.

Immunotherapy for Alzheimer's disease

Morgan D.

J Intern Med. 2011 Jan;269(1):54-63. doi: 10.1111/j.1365-2796.2010.02315.x.

PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease

Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D.

Alzheimer Dis Assoc Disord. 2011 Jul-Sep;25(3):206-12. doi: 10.1097/WAD.0b013e318204b550.

Therapeutic targets in Alzheimer's disease and related tauopathies

Corbo CP, Alonso Adel C.

Prog Mol Biol Transl Sci. 2011;98:47-83. doi: 10.1016/B978-0-12-385506-0.00002-8.

Voltage-dependent anion channel as a resident protein of lipid rafts: post-transductional regulation by estrogens and involvement in neuronal preservation against Alzheimer's disease

Herrera JL, Diaz M, Hernández-Fernaud JR, Salido E, Alonso R, Fernández C, Morales A, Marin R.

J Neurochem. 2011 Mar;116(5):820-7. doi: 10.1111/j.1471-4159.2010.06987.x. Epub 2011 Jan 7.

A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people

Kwok T, Lee J, Law CB, Pan PC, Yung CY, Choi KC, Lam LC.

Clin Nutr. 2011 Jun;30(3):297-302. doi: 10.1016/j.clnu.2010.12.004. Epub 2011 Jan 8.

Current perspectives on pharmacotherapy of Alzheimer's disease

Chopra K, Misra S, Kuhad A.

Expert Opin Pharmacother. 2011 Feb;12(3):335-50. doi: 10.1517/14656566.2011.520702. Epub 2011 Jan 11.

Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, Logroscino G, Seripa D, Pilotto A.

Expert Opin Investig Drugs. 2011 Mar;20(3):325-41. doi: 10.1517/13543784.2011.550572. Epub 2011 Jan 11.

EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study

Vellas B, Sol O, Snyder PJ, Ousset PJ, Haddad R, Maurin M, Lemarié JC, Désiré L, Pando MP; EHT0202/002 study group.

Curr Alzheimer Res. 2011 Mar;8(2):203-12. doi: 10.2174/156720511795256053.

Mitochondrion-specific antioxidants as drug treatments for Alzheimer disease

Palacios HH, Yendluri BB, Parvathaneni K, Shadlinski VB, Obrenovich ME, Leszek J, Gokhman D, Gąsiorowski K, Bragin V, Aliev G.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):149-62. doi: 10.2174/187152711794480474.

Alzheimer's disease: from pathogenesis to disease-modifying approaches

Galimberti D, Scarpini E.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):163-74. doi: 10.2174/187152711794480438.

Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease

Blesa González R, Boada Rovira M, Martínez Parra C, Gil-Saladié D, Almagro CA, Gobartt Vázquez AL; en representación del grupo de investigadores del estudio kAPA.

Neurologia. 2011 Jun;26(5):262-71. doi: 10.1016/j.nrl.2010.10.007. Epub 2011 Jan 11.

Simvastatin and other HMG-CoA reductase inhibitors on brain cholesterol levels in Alzheimer's disease

Longenberger J, Shah ZA.

Curr Alzheimer Res. 2011 Jun;8(4):434-42. doi: 10.2174/156720511795745393.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias